Giovanni Pericolini
Director of Finance/CFO at Medicxi Ventures (Jersey) Ltd.
Network origin in Giovanni Pericolini first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Medicxi Ventures (Jersey) Ltd.
 Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.
25
| Private Company | Investment Managers | 25 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Giovanni Pericolini via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
Index Ventures SA
 Index Ventures SA Investment ManagersFinance Index Ventures SA (Index Ventures) is a venture capital firm founded in 1996 by Neil Alexander Rimer, Gluseppe Zocco and Gerald Rimer. The firm is headquartered in Geneva, Switzerland. | Investment Managers | Founder Private Equity Analyst Private Equity Analyst Private Equity Investor Private Equity Analyst | |
| University of Cambridge | College/University | Doctorate Degree Doctorate Degree Graduate Degree Graduate Degree | |
| CENTESSA PHARMACEUTICALS PLC | Pharmaceuticals: Major | Chairman Corporate Officer/Principal Director/Board Member | |
Z Factor Ltd.
 Z Factor Ltd. BiotechnologyHealth Technology Z Factor Ltd. operates as a drug discovery company. It identifies and develops therapeutic agents to treat alpha-1-antitrypsin deficiency. The company was founded by James Huntington in 2015 and is headquartered in Babraham, the united Kingdom. | Biotechnology | Director/Board Member Director/Board Member Corporate Officer/Principal | |
Levicept Ltd.
 Levicept Ltd. Pharmaceuticals: GenericHealth Technology Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom. | Pharmaceuticals: Generic | Chairman Director/Board Member Director/Board Member | |
| Imperial College London | College/University | Undergraduate Degree Doctorate Degree Undergraduate Degree | |
Palladio Biosciences, Inc.
 Palladio Biosciences, Inc. BiotechnologyHealth Technology Palladio Biosciences, Inc. develops transformative medicines for orphan diseases. Its pipeline includes Lixivaptan, a selective vasopressin V2 receptor antagonist for the treatment of polycystic kidney disease, a life-threatening genetic disease. The company was founded by Lorenzo Pellegrini in 2015 and is headquartered in Newtown, PA. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
UltraHuman Ltd.
 UltraHuman Ltd. Miscellaneous Commercial ServicesCommercial Services UltraHuman Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Sandwich, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member | |
Inhibitaxin Ltd.
 Inhibitaxin Ltd. BiotechnologyHealth Technology Inhibitaxin Ltd. engages in research and development on biotechnology. The company was founded by Simon Lempriere Westbrook and Kevin S. Johnson in 2013 and is headquartered in Kent, the United Kingodm. | Biotechnology | Founder Director/Board Member | |
Impact Biomedicines, Inc.
 Impact Biomedicines, Inc. Medical SpecialtiesHealth Technology Impact Biomedicines, Inc. engages in the development of cancer treatments. It engages in the development of fedratinib, a potent and selective oral molecule JAK2 kinase inhibitor for the treatment of myelofibrosis and polycythemia vera. The company was founded by John Hood, Catriona Jamieson and Raghu Saripalli in 2016 and is headquartered in San Diego, CA. | Medical Specialties | Director/Board Member Director/Board Member | |
Gadeta BV
 Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Medical Specialties | Director/Board Member Director/Board Member | |
| IPSEN | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
ApcinteX Ltd.
 ApcinteX Ltd. BiotechnologyHealth Technology ApcinteX Ltd. develops and markets anticoagulant APC pathway to treat haemophilia. The company is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member Founder | |
| Kaerus Bioscience Ltd. | Chairman Director/Board Member | ||
| Index Ventures (UK) LLP | Investment Managers | Private Equity Investor Private Equity Investor | |
Xenikos BV
 Xenikos BV Medical SpecialtiesHealth Technology Xenikos BV focuses on the development of immunotherapies for the treatment of patients suffering from immune diseases. It is developing a combination of two toxin-loaded anti-T-cell antibodies, T-Guard, as a therapeutic tool for resetting the body's immune system in T-cell mediated diseases. The company was founded by Ypek van Oosterhout in September 2009 and is headquartered in Nijmegen, the Netherlands. | Medical Specialties | Director/Board Member Director/Board Member | |
Critical Pressure Ltd.
 Critical Pressure Ltd. Pharmaceuticals: MajorHealth Technology Critical Pressure Ltd. engages in research and experimental development on biotechnology. The firm develops products to treat vascular dysfunction and shock. The company is headquartered in Babraham, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
| COMPUGEN LTD. | Biotechnology | Chairman Director/Board Member | |
Epsilon-3 Bio Ltd
 Epsilon-3 Bio Ltd Pharmaceuticals: OtherHealth Technology Epsilon-3 Bio Ltd. develops compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders. The company was founded by Martin W. Edwards, Konstantinos Efthymiopoulos, David J. Grainger and Christian De La Tour on June 18, 2010 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Other | Director/Board Member Director/Board Member | |
| AEGERION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| MOLECULAR PARTNERS AG | Biotechnology | Director/Board Member Director/Board Member | |
Janpix Holdings, Inc.
 Janpix Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Janpix Holdings, Inc. engages in provision of research and experimental development on biotechnology. The company was founded by Patrick T. Gunning and Cortes Pierre and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
| MINERVA NEUROSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
NormOxys, Inc.
 NormOxys, Inc. Pharmaceuticals: MajorHealth Technology NormOxys, Inc. develops small-molecule therapeutics for the treatment of cancer. Its major product is OXY111A. The company was founded by Conrad J Bletzer, Jr. Claude Nicoalu, Jean-Mearie Lehn, Gay Goodman, Ruth Greferath and Roscoe Brady in 2004 and is headquartered in Brighton, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Morphogen-IX Ltd.
 Morphogen-IX Ltd. Miscellaneous Commercial ServicesCommercial Services Morphogen-IX Ltd. operates as a biotechnology company. It develops bone morphogenetic proteins as a novel therapy for the treatment of Pulmonary Arterial Hypertension. The company was founded in 2015 and is headquartered in Babraham, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Founder | |
XO1 Ltd.
 XO1 Ltd. Medical/Nursing ServicesHealth Services XO1 Ltd. develops a novel anticoagulant drug. The firm operates as a biopharmaceutical company. The company was founded by David J. Grainger on February 28, 2013 and is headquartered in High Wycombe, the United Kingdom. | Medical/Nursing Services | Founder Founder | |
ProFibrix BV
 ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member | |
Human Antibody Factory Ltd.
 Human Antibody Factory Ltd. BiotechnologyHealth Technology Human Antibody Factory Ltd. provides research and experimental development on biotechnology. The company was founded by David John Grainger and is headquartered in Hatfield, the United Kingdom. | Biotechnology | Director/Board Member Founder | |
| Stx Pharma Ltd. | Director/Board Member Founder | ||
Rebalance (Cambridge) Ltd.
 Rebalance (Cambridge) Ltd. Miscellaneous Commercial ServicesCommercial Services Rebalance (Cambridge) Ltd. provides research and experimental development on biotechnology. The company was founded on December 6, 2016 and is headquartered in Hatfield, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
SDS Therapeutics Ltd.
 SDS Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services SDS Therapeutics Ltd. is a British biotechnology company founded in 2020 that provides research and development services. The company is based in Cambridge, UK. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Stealthyx Therapeutics Ltd.
 Stealthyx Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Stealthyx Therapeutics Ltd. operates drug delivery system technology. The company was founded by Yuti Chernajovsky and Eileen Janis Anderson in 2002 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Kymo Therapeutics Ltd.
 Kymo Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Kymo Therapeutics Ltd. develops and commercializes therapeutic products . The company was founded on May 23, 2016 and is headquartered in Hatfield, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Andera Partners SCA
 Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France. | Investment Managers | Corporate Officer/Principal | |
LinguaFlex, Inc.
 LinguaFlex, Inc. Medical SpecialtiesHealth Technology LinguaFlex, Inc. develops, manufactures and distributes medical devices for the treatment of sleep apnea. It offers the LinguaFlex Tongue Retractor which is a minimally invasive device designed to be inserted into the tongue by a thin needle. The LinguaFlex Tongue Retractor is designed not to interfere with normal tongue functions such as speech and swallowing and to be removed or replaced in a doctor’s office in a short period of time without the need for anesthesia. The company was founded by Ira Sanders in 2007 and is headquartered in Pittsburgh, PA. | Medical Specialties | Director/Board Member | |
Diasome Pharmaceuticals, Inc.
 Diasome Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Diasome Pharmaceuticals, Inc. operates as a clinical stage diabetes therapeutics company which designs and develops insulin-based therapies for the treatment of diabetes. It focuses on the clinical and commercial development of breakthrough therapies for diabetes and obesity. The company’s technology platform is based on the use of its proprietary Hepatocyte Directed Vesicle or HDV, nanotechnology to deliver a wide range of critically necessary hormones and drugs to the liver, the body’s primary site of glucose storage. The firm’s HDV system is designed to fundamentally improve the way in which insulin works in people with diabetes by enabling much greater amounts of injected insulin to reach hepatocytes, the liver’s glucose storing cells. The company was founded by Len Rosenberg, Lance Converse, W. Blair Geho and Robert Geho in 2004 and is headquartered in Cleveland, OH. | Pharmaceuticals: Major | Director/Board Member | |
| Medicxi Ventures (Jersey) Ltd. (Switzerland) | Corporate Officer/Principal | ||
Villaris Therapeutics, Inc.
 Villaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Villaris Therapeutics, Inc. is an asset-centric biopharmaceutical company. The company is based in Cary, NC. The company was founded in 2019 by John Harris. The CEO is Andrea Epperly. | Pharmaceuticals: Major | Director/Board Member | |
| Université Paris Nanterre | College/University | Doctorate Degree | |
Kaerus Bioscience France SASU
 Kaerus Bioscience France SASU Miscellaneous Commercial ServicesCommercial Services Kaerus Bioscience France SASU engages in research and development in biotechnology. The company was founded on February 23, 2017 and is headquartered in Orléans, France. | Miscellaneous Commercial Services | Chief Executive Officer | |
| Pega-One SAS | Director/Board Member |
Statistics
International
| United Kingdom | 23 |
| United States | 14 |
| Netherlands | 7 |
| France | 6 |
| Switzerland | 4 |
Sectoral
| Health Technology | 31 |
| Commercial Services | 8 |
| Finance | 4 |
| Consumer Services | 4 |
| Health Services | 3 |
Operational
| Director/Board Member | 203 |
| Corporate Officer/Principal | 40 |
| Founder | 34 |
| Chairman | 31 |
| Private Equity Investor | 30 |
Most connected contacts
| Insiders | |
|---|---|
| Paul Sekhri | 62 |
| Michèle Ollier | 40 |
| Francesco de Rubertis | 36 |
| David Grainger | 29 |
| Giuseppe Zocco | 26 |
| Sanford Zweifach | 22 |
| Kevin Johnson | 22 |
| Moncef Slaoui | 22 |
| Aaron Kantoff | 19 |
| Alasdair Thong | 15 |
| Jonathan Edwards | 12 |
| Giovanni Mariggi | 11 |
| Trevor Baglin | 8 |
| Benjamin Perry | 4 |
| Matthew Lumley | 4 |
- Stock Market
- Insiders
- Giovanni Pericolini
- Company connections
